

November 01, 2021

To,
~~Dy. General Manager~~
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
~~The Manager – Listing,~~
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub:- Board Meeting

We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, November 12, 2021, inter alia, to consider and approve the Unaudited Financial ~~Results of the Company for the Second Quarter and Half Year ended~~ September 30, 2021.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2021 to November 14, 2021 (both days inclusive) for the purpose of approval of Unaudited Financial ~~Results for the Second Quarter and Half Year ended September 30, 2021.~~

The above is for your information.

Thanking you.

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary Compliance Officer



Tel: 4018 9999 / 4018 9879
Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 / 4018 9879 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com